|
Tuesday December 04, 2007
Hathaway's (HWYI) Subsidiary DDI Signs
Prominent Physicians for Its Scientific Advisory Board
Past Chairman of American Diabetes Association Now Part
of DDI Team
PALO ALTO, CA--(MARKET WIRE)--Dec 4, 2007 -- Hathaway Corporation
(Other OTC:HWYI.PK - News) announced that its subsidiary, Diabetes
Detection, Inc. (DDI), has been successful in signing two of the
leading physicians and clinical researchers of Neuropathy and Diabetes
treatments, for its Scientific Advisory Board.
The highly respected physicians, who are authors of numerous research
studies, papers and textbooks, have played significant leadership
roles with various international Diabetes-related associations,
including holding a past chairmanship of the American Diabetes Association.
They have been responsible for, among other things, shaping the
ADA's official position on Diabetic Neuropathies, and are strong
and outspoken proponents for vibration testing for Neuropathy, the
basis for DDI's technology.
The physicians are now actively helping with fine-tuning and enhancing
the functionality of the DDI product, and with the structure and
logistics of clinical trials.
"This is a major breakthrough," said Sadruddin Currimbhoy,
DDI's CEO. "DDI's product has received tremendous validation
with these signings. These individuals are the leaders in our field,
and their involvement with DDI will be instrumental in proving the
viability of our technology, and also with achieving widespread
acceptance and adoption for the DDI product across the physician
community."
DDI's first commercial offering is currently in its third generation
prototype stage, and progressing rapidly towards marketability.
The Diabetes Market
The American Diabetes Association estimates that 20.8m, or 7% of
the entire population of the United States has diabetes -- with
this expected to continue to grow at a dramatic pace. The ADA estimates
that direct medical and indirect expenditures attributable to diabetes
in the US alone are $132 billion (2002).
About DDI
Diabetes Detection Inc.'s patent-pending Neuropathy testing technology
converged with communications devices, facilitates the early detection
of Diabetes, which is now in epidemic proportions, affecting 140m
people worldwide, and predicted to grow to 300m in 25 years (Source:
WHO).
Forward-Looking Statements
This press release may contain forward-looking statements covered
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements relate to, among other
things, plans and timing for the introduction or enhancement of
our services and products, statements about future market conditions,
supply and demand conditions, and other expectations, intentions
and plans contained in this press release that are not historical
fact and involve risks and uncertainties. Our expectations regarding
future revenues depend upon our ability to develop and supply products
and services that we may not produce today and that meet defined
specifications. When used in this press release, the words "plan,"
"expect," "believe," and similar expressions
generally identify forward-looking statements. These statements
reflect our current expectations. They are subject to a number of
risks and uncertainties, including, but not limited to, changes
in technology and changes in pervasive markets.
Contact:
FutureTechIR for Hathaway Corporation
Investor Relations
(817) 812-2105
|
